The influencing of respiratory adverse effects of enalapril Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Pharmacologic effects of acute administration of Ipratropium on top of maintenance treatment with tiotropium Source: Eur Respir J 2003; 22: Suppl. 45, 67s Year: 2003
Overdosing on immediate-release morphine solution has predictable adverse effects Source: Eur Respir J, 50 (3) 1701091; 10.1183/13993003.01091-2017 Year: 2017
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Cardiovascular adverse effects during itraconazole therapy Source: Eur Respir J 2008; 32: 240 Year: 2008
Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018 Year: 2019
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Once-daily administration of indacaterol does not induce tachyphylaxis in vivo Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Lack of tolerance to the bronchoprotective effect with intermittent administration of salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 710s Year: 2006
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
Effect of long-term treatment with inhaled furosemide and nedocromil sodium on exercise-induced broncho-obstruction in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 495s Year: 2001
Long-term safety of medium- and high-dose mometasone furoate/formoterol combination in persistent asthmatics: Analysis of adverse event incidence, plasma cortisol, and ocular changes Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Effects of hydrocortisone on acute beta-blocker and histamine induced bronchoconstriction Source: Annual Congress 2011 - Asthma management and response Year: 2011